2024-06-28 04:35:51 ET
Summary
- Illumina has finally completed the divestiture of GRAIL, ending a disastrous chapter in its history.
- The Company paid $8bn to acquire the cancer testing business it helped to create, which proved to be a disastrous mistake, triggering three years of share price losses.
- Newly spun-out GRAIL faces challenges in the competitive cancer testing market, while Illumina returns to its profitable gene sequencing business.
- GRAIL's target market is still in its infancy, and the company's high cash burn is problematic. Shares of the newly listed company look cheap, but the current valuation is arguably fair.
- ILMN trades at ~4x forward sales, and will now renew its focus on a market it knows and which has historically served it well, helping the company achieve a share price of >$500 - Illumina is the horse to back in my view.
Investment Overview - Illumina Says Goodbye To GRAIL, & It's Worst Ever Business Decision
This week, Illumina ( ILMN ), the San Diego, California-based gene sequencing giant, brought an end to a disastrous chapter in its relatively short history by completing the divestiture of GRAIL, the cancer testing business it helped to found....
Read the full article on Seeking Alpha
For further details see:
Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out